123 related articles for article (PubMed ID: 8826889)
21. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan.
Wada M; Mizoguchi H; Kuriya SI; Taguchi H; Kawamura T; Maekawa I; Shimazaki C; Sato Y; Niho Y; Miyazaki T; Shibata A; Kitani T; Hamajima N; Ohno R
Br J Haematol; 2000 Jun; 109(4):805-14. PubMed ID: 10929034
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
Palumbo A; Boccadoro M; Garino LA; Gallone G; Frieri R; Pileri A
Eur J Haematol; 1992 Aug; 49(2):93-7. PubMed ID: 1397246
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
24. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
[TBL] [Abstract][Full Text] [Related]
25. [The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].
Zhao Y; Dou LP; Wang SH; Bo J; Wang QS; Huang WR; Jing Y; Gao CJ; Li HH; Zhu HY; Han XP; Yu L
Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):762-4. PubMed ID: 21092447
[TBL] [Abstract][Full Text] [Related]
26. Potential value of vintristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma.
Collin R; Greaves M; Preston FE
Eur J Haematol; 1987 Sep; 39(3):203-8. PubMed ID: 3678471
[TBL] [Abstract][Full Text] [Related]
27. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
[TBL] [Abstract][Full Text] [Related]
28. Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial.
Offidani M; Olivieri A; Montillo M; Rupoli S; Centurioni R; Alesiani F; Marchegiani G; Pieroni S; Catarini M; Pelliccia G; Altilia F; Leoni P
Haematologica; 1998 Jan; 83(1):40-7. PubMed ID: 9542322
[TBL] [Abstract][Full Text] [Related]
29. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
Aviles A; Duque G; Talavera A; Guzman R
Leuk Lymphoma; 1996 Feb; 20(5-6):495-9. PubMed ID: 8833409
[TBL] [Abstract][Full Text] [Related]
30. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
31. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
[TBL] [Abstract][Full Text] [Related]
32. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
35. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
[TBL] [Abstract][Full Text] [Related]
38. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G
Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477
[TBL] [Abstract][Full Text] [Related]
39. VAD chemotherapy for refractory multiple myeloma.
Lokhorst HM; Meuwissen OJ; Bast EJ; Dekker AW
Br J Haematol; 1989 Jan; 71(1):25-30. PubMed ID: 2644970
[TBL] [Abstract][Full Text] [Related]
40. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
